Statements (21)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:Company
|
| gptkbp:bfsLayer |
4
|
| gptkbp:bfsParent |
gptkb:Teva_USA
|
| gptkbp:acquired |
gptkb:Company
|
| gptkbp:dissolved |
gptkb:2011
|
| gptkbp:employees |
approximately 1,000
|
| gptkbp:founded |
gptkb:1998
|
| gptkbp:founder |
Dr. Michael A. Friedman
|
| gptkbp:headquarters |
Frazer, Pennsylvania
|
| https://www.w3.org/2000/01/rdf-schema#label |
Cephalon, Inc.
|
| gptkbp:industry |
gptkb:drug
|
| gptkbp:key_people |
Kevin G. Mc Laughlin
|
| gptkbp:products |
gptkb:Provigil
Actiq Fentora Nuvigil |
| gptkbp:revenue |
$1.1 billion (2010)
|
| gptkbp:subsidiary |
Cephalon Australia Pty Ltd.
Cephalon Canada Inc. Cephalon UK Ltd. |
| gptkbp:website |
www.cephalon.com
|